Conclusions
Erenumab and galcanezumab reduced mean headache days, acute migraine
specific medication days, Headache Impact Test score, Migraine
Disability Assessment Test score and Visual Analogue Scale score after 3
and 6 doses in real-world patients diagnosed with chronic or episodic
migraine who previously did not respond to, at least, three different
oral preventive therapies.
Erenumab and galcanezumab exhibit a great safety profile, rarely leading
to discontinuation because of poor tolerance. Nevertheless, further
studies in real world setting are required since the adverse events are
frequent and though mild, some can lead to treatment interruption.
Erenumab and galcanezumab reduced by a half the number of acute migraine
specific medication days in, at least, a 50% of the patients enrolled
in this study. Therefore, both monoclonal antibodies seem to be
promising therapeutic options even in patients with difficult-to-treat
migraine.